uniQure (QURE) Other Non-Current Liabilities (2015 - 2026)
uniQure (QURE) posted quarterly Other Non-Current Liabilities of $18.1 million for Q2 2026, up 13.7% year-over-year from $15.9 million in Q2 2025, and up 6.37% quarter-over-quarter from $17.0 million in Q1 2026.
uniQure (QURE) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
uniQure's Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $18.1 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 13.7% year-over-year to $18.1 million; the TTM figure through Jun 2026 stood at $18.1 million (up 13.7% YoY), while the FY2025 annual figure was $18.7 million, up 72.52% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $18.1 million, up from $17.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $42.2 million in Q1 2024, with the low at $9.3 million in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $23.9 million (2022), against an average of $25.9 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities surged 900.97% in 2022, then tumbled 70.14% in 2025.
- uniQure's Other Non-Current Liabilities stood at $9.3 million in 2022, then jumped by 58.51% to $14.8 million in 2023, then decreased by 26.6% to $10.9 million in 2024, then surged by 72.52% to $18.7 million in 2025, then fell by 3.33% to $18.1 million in 2026.
- Business Quant data shows QURE's Other Non-Current Liabilities at $18.1 million in Q2 2026, $17.0 million in Q1 2026, and $18.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | uniQure | 3.37 Bn | 3.37 Bn | 5.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.11 Mn |
| Mar 31, 2026 | 17.03 Mn |
| Dec 31, 2025 | 18.74 Mn |
| Sep 30, 2025 | 17.75 Mn |
| Jun 30, 2025 | 15.93 Mn |
| Mar 31, 2025 | 12.60 Mn |
| Dec 31, 2024 | 10.86 Mn |
| Sep 30, 2024 | 41.40 Mn |
| Jun 30, 2024 | 40.10 Mn |
| Mar 31, 2024 | 42.20 Mn |
| Dec 31, 2023 | 14.80 Mn |
| Sep 30, 2023 | 40.70 Mn |
| Jun 30, 2023 | 37.20 Mn |
| Mar 31, 2023 | 36.90 Mn |
| Dec 31, 2022 | 9.33 Mn |
| Sep 30, 2022 | 32.70 Mn |
| Jun 30, 2022 | 29.10 Mn |
| Mar 31, 2022 | 31.10 Mn |
| Dec 31, 2021 | 29.54 Mn |
| Sep 30, 2021 | 23.78 Mn |